Möchten Sie immer auf dem neuesten Stand bleiben?
Erstellen Sie noch heute ein Leserkonto, um die Branchen und Unternehmen zu verfolgen, die Sie interessieren, und passen Sie Ihr Nachrichten-Dashboard an.
-
LOUISVILLE, CO--(Marketwire - April 15, 2010) - GlobeImmune, Inc. anunció hoy los datos finales de la fase 2b de GI-5005, el producto candidato Tarmogen(R) bajo investigación de la...
-
LOUISVILLE, CO--(Marketwire - March 17, 2010) - GlobeImmune Inc. today announced that three abstracts related to GI-5005, the company's hepatitis C (HCV) product candidate, have been accepted...
-
LOUISVILLE, CO--(Marketwire - January 19, 2010) - GlobeImmune Inc., a company developing novel therapies for patients with cancer and infectious diseases, today announced a Series E Preferred Stock...
-
LOUISVILLE, CO--(Marketwire - November 2, 2009) - GlobeImmune Inc. will present Phase 2b data today at the 60th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)...
-
LOUISVILLE, CO--(Marketwire - October 6, 2009) - GlobeImmune Inc. today announced that a late breaking abstract related to GI-5005, its investigational hepatitis C virus (HCV) product candidate, has...
-
LOUISVILLE, CO and SUMMIT, NJ--(Marketwire - May 15, 2009) - GlobeImmune, Inc. and Celgene Corporation (NASDAQ: CELG) today announced a worldwide strategic collaboration focused on the discovery,...
-
LOUISVILLE, CO--(Marketwire - April 24, 2009) - Twelve-week Phase 2 clinical trial data show that patients treated with GI-5005, GlobeImmune's targeted molecular immunogen (Tarmogen®) for the...
-
LOUISVILLE, CO--(Marketwire - April 16, 2009) - GlobeImmune, Inc. today announced the initiation of a Phase 1 clinical trial to investigate the safety and tolerability of a new Tarmogen, GI-6207, in...
-
LOUISVILLE, CO--(Marketwire - November 1, 2008) - Four-week Phase 2 clinical trial data show that GI-5005, GlobeImmune's hepatitis C virus (HCV) targeted molecular immunogen (Tarmogen®), doubled...
-
LOUISVILLE, CO--(Marketwire - October 28, 2008) - GlobeImmune Inc. today announced that four-week data from the on-going Phase 2 clinical trial for GI-5005, the Company's therapeutic vaccine...